ArticleCancer biomarkers : section A of Disease markers2025
BUB1, miR-495-3p, and E2F1/E2F8 axis is associated with poor prognosis of breast cancer patients and infiltration of Th2 cells in the tumor microenvironment.
Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects ofExperimental and therapeutic medicine · 2026Article
- Hypoxia Triggers ALYREF-Mediated mThe Kaohsiung journal of medical sciences · 2026Article
- hsa-let-7b-5p-associated BUB1/TMPO-AS1 ceRNA axis identified as a potential biomarker in lung adenocarcinoma.Cell division · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer, the most common cancer in women, is characterized by cell cycle dysregulation and chromosome segregation errors, leading to mitotic catastrophe and genomic instability. Understanding these molecular mechanisms is crucial for better diagnosis and treatment. We used databases like TIMER 2.0, UALCAN, and Oncomine to determine the differential expression of Budding uninhibited by benzimidazole 1 (BUB1) in normal and pan-cancer tissues. we also used the Kaplan-Meier Plotter database to analyze gene expression associations with survival outcomes, bc-GenExMiner v5.0 to analyze BUB1 gene expression and histological subtypes, and ctcRbase and miR-TV to identify microRNAs associated with BUB1 expression in breast cancer. Our data show that BUB1 expression is overexpressed in breast cancer tumors, metastatic tissues, and circulating tumor cells, leading to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.